- 6 patents filed for pain management, eating disorders and epilepsy
- Additional patents underway for PTSD, depression, Alzheimer’s and Parkinson’s disease
- Revenue potential of each cannabis-based therapy could fetch between $100 million to $500 million
India Globalization Capital (NYSE AMERICAN: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of Alzheimer’s, cachexia, pain, and other life-altering conditions. The company’s most recent research and development focus continues to be on readying a line of cannabis-based products targeting Alzheimer’s disease utilizing novel data (http://dtn.fm/st4Ef). This cannabis-based combination therapy shows promise for Alzheimer’s sufferers, says IGC CEO Ram Mukunda.
“As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss. These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50%, and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease,” Mukunda says, adding the company is pursuing a patent filing that protects the company’s breakthrough therapy.
Four products currently in the company’s medical trial pipeline are Hyalolex, aimed at reducing beta-amyloid building up in Alzheimer’s patients; Natrinol, or synthetic THC, which has application for nausea, vomiting and loss of appetite in patients with AIDS and cancer; Caesafin, a combination therapy used to ease seizures in dogs and cats; and Serosapse, which addresses various endpoints in Parkinson’s disease.
IGC’s unique strategy reduces regulatory approval time and development costs because its chosen categories face lower regulatory burdens. Instead of pursuing full novel drug applications, which take anywhere from 7-9 years in clinical trials and cost hundreds of millions before securing FDA approval, IGC is developing cannabis-based drugs that could be commercialized in less than two years and at a cost of between $2 million to $3 million per product. These products will then be made available through medical cannabis dispensaries, which means a faster development timeline with a much lower end cost than through the traditional pharmaceutical pipeline.
Approximately 47 million people throughout the world are living with dementia, according to the Alzheimer’s Association, with 5 million Americans diagnosed with the neurological disorder (http://dtn.fm/utH2y). IGC expects to soon begin clinical trials for its Alzheimer’s combination therapy, putting it on track to bring its phytocannabinoid-based pharmaceutical products to market in an expeditious and cost-effective manner.
For more information, visit the company’s website at www.IGCInc.us
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
